Tissue, days post-infection (dpi) and the top 10 most significant genes with increased and decreased expression with valid gene symbols for the response contrasts. حسب Gillian P. McHugo (8965919)

"…<p>Tissue, days post-infection (dpi) and the top 10 most significant genes with increased and decreased expression with valid gene symbols for the response contrasts.…"

The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. حسب Shuhuan Zhang (748003)

Youthful systemic milieu in young recipients decreased apoptosis and oxidative stress damage in allografts, and promoted proliferation. حسب Chengjun Yu (12136227)

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. حسب Zahra Hosseininia (22265113)

Loss of MAP4K4 expression causes a decrease in the number of neutrophils. حسب Guihua Wang (286390)

Expression of lipid biosynthetic genes is decreased with polyamine depletion. حسب Yazmin E. Cruz-Pulido (20285238)

The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. حسب Gui Araujo (22170819)

"…(C) Mutualism also promotes an increase in network connectance when introduced into assembled communities, while stopping mutualistic interactions from entering an assembled system slowly decreases it. (D) As a result, the introduction of mutualistic interactions promotes a growth in complexity in communities where it was once established as low, while stopping the introduction of further mutualistic interactions causes a slight decrease in complexity. …"

Madrasin decreases transcription of protein-coding genes. حسب Michael Tellier (8284752)

Madrasin decreases transcription of protein-coding genes. حسب Michael Tellier (8284752)

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

الموضوعات: